Download MendeleyStructure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.
He, R., Wang, J., Yu, Z.H., Moyers, J.S., Michael, M.D., Durham, T.B., Cramer, J.W., Qian, Y., Lin, A., Wu, L., Noinaj, N., Barrett, D.G., Zhang, Z.Y.(2022) J Med Chem 65: 13892-13909
- PubMed: 36197449
- DOI: https://doi.org/10.1021/acs.jmedchem.2c01143
- Primary Citation of Related Structures:
7UW6 - PubMed Abstract:
Protein tyrosine phosphatases constitute an important class of drug targets whose potential has been limited by the paucity of drug-like small-molecule inhibitors. We recently described a class of active-site-directed, moderately selective, and potent inhibitors of the low-molecular-weight protein tyrosine phosphatase (LMW-PTP). Here, we report our extensive structure-based design and optimization effort that afforded inhibitors with vastly improved potency and specificity. The leading compound inhibits LMW-PTP potently and selectively ( K i = 1.2 nM, >8000-fold selectivity). Many compounds exhibit favorable drug-like properties, such as low molecular weight, weak cytochrome P450 inhibition, high metabolic stability, moderate to high cell permeability (Papp > 0.2 nm/s), and moderate to good oral bioavailability (% F from 23 to 50% in mice), and therefore can be used as in vivo chemical probes to further dissect the complex biological as well as pathophysiological roles of LMW-PTP and for the development of therapeutics targeting LMW-PTP.
Organizational Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, 307 E Merrill Street, Indianapolis, Indiana 46225, United States.
